European Pharmaceutical Market Access, Pricing and Reimbursement 2016

This year's agenda will have a strong focus on the future of pricing and reimbursement. Key topics include: -Updates on AMNOG and its implication on pricing and reimbursement -How biosimilars are affecting your pricing strategy -Capture on emerging markets’ regulatory framework to adapt your market access and PandR models -Orphan drugs using recent examples to highlight the impact on pricing -Cancer drug funding and budget cuts in the UK -Innovative solutions beyond the pill -Japanese, American, Nordic and Turkish regional update Key speakers in 2016: -Bertram Haussler, Chairman of the Board of Management, IGES -Simone Breitkopf, Head HEOR, Governmental and Public Affairs, Alcon -Ulf Staginnus, Head Market Access Oncology, Region Europe, Baxalta -Gordon Spencer, Regional Market Access Lead - EU and Canada, Shire International GmbH -Alexander Natz, Secretary General, EUCOPE -David Watson, Director of Pricing and PPRS, Association of the British Pharmaceutical Industry -Panos Kefalas, Head of Health Economics and Market Access, Cell and Gene Therapy Catapult and many more. Don't miss the workshop.